CD151 is associated with prostate cancer cell invasion and lymphangiogenesis in vivo

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 241-247

  Detchokul, Sujitra ^a   Newell, Bradley ^a   Williams, Elizabeth D ^a,b,c   Frauman, Albert G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Angiogenesis; Cell invasion; Lymphangiogenesis and prostate cancer; Metastasis; Tetraspanins

Indexed keywords

ANDROGEN; CD151 ANTIGEN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CAPILLARY DENSITY; CELL INVASION; CELL STRAIN DU 145; CELL STRAIN LNCAP; CELL STRAIN PC 3; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN ISOLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD151; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; INTEGRINS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MALE; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891951106     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2823     Document Type: Article

References (46)

1. Liu AY, Roudier MP and True LD: Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 165: 1543-1556, 2004.
2. Liu AY and True LD: Characterization of prostate cell types by CD cell surface molecules. Am J Pathol 160: 37-43, 2002.
3. Liu AY: Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60: 3429-3434, 2000.
4. Hemler ME: Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6: 801-811, 2005.
5. Berditchevski F: Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 114: 4143-4151, 2001.
6. Levy S and Shoham T: Protein-protein interactions in the tetraspanin web. Physiology 20: 218-224, 2005.
7. Testa JE, Brooks PC, Lin JM and Quigley JP: Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res 59: 3812-3820, 1999.
8. Longo N, Yanez-Mo M, Mittelbrunn M, et al: Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 98: 3717-3726, 2001.
9. Nishiuchi R, Sanzen N, Nada S, et al: Potentiation of the ligand-binding activity of integrin α3β1 via association with tetraspanin CD151. Proc Natl Acad Sci USA 102: 1939-1944, 2005.
10. Ang J, Lijovic M, Ashman LK, Kan K and Frauman AG: CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Cancer Epidemiol Biomarkers Prev 13: 1717-1721, 2004.
11. Ang J, Fang BL, Ashman LK and Frauman AG: The migration and invasion of human prostate cancer cell lines involves CD151 expression. Oncol Rep 24: 1593-1597, 2010.
12. Sincock PM, Mayrhofer G and Ashman LK: Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63 and α5β1 integrins. J Histochem Cytochem 45: 515-525, 1997.
13. Geary SM, Cambareri AC, Sincock PM, Fitter S and Ashman LK: Differential tissue expression of epitopes of the tetraspanin CD151 recognised by monoclonal antibodies. Tissue Antigens 58: 141-153, 2001.
14. Bradford MM: Rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
15. Zeng Y, Opeskin K, Goad J and Williams ED: Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 66: 9566-9575, 2006.
16. Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in a athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154, 1989.
17. Mehta R, Kyshtoobayeva A, Kurosaki T, et al: Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 7: 81-88, 2001.
18. Wroel T, Mazur G, Dziegiel P, et al: Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes. Folia Histochem Cytobiol 44: 43-47, 2006.
19. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
20. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993.
21. Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36: 169-180, 1995.
22. Quaranta V: Motility cues in the tumor microenvironment. Differentiation 70: 590-598, 2002.
23. Schmelz M, Cress AE, Scott KM, et al: Different phenotypes in human prostate cancer: α6 or α3 integrin in cell-extracellular adhesion sites. Neoplasia 4: 243-254, 2002.
24. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS and Cress AE: Characterization of integrin subunits, cellular adhesion and tumorgenicity of 4 human prostate cell-lines. J Cancer Res Clin Oncol 119: 637-644, 1993.
25. 1 and TM4SF protein CD151. J Biol Chem 275: 9230-9238, 2000.
26. Kazarov AR, Yang X, Stipp CS, Sehgal B and Hemler ME: An extracellular site on tetraspanin CD151 determines α3 and α6 integrin-dependent cellular morphology. J Cell Biol 158: 1299-1309, 2002.
27. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW and Greenberg NM: Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61: 2736-2743, 2001.
28. Steiner I, Jung K, Miller K, Stephan C and Erbersdobler A: Expression of endothelial factors in prostate cancer: A possible role of caveolin-1 for tumour progression. Oncol Rep 27: 389-395, 2012.
29. Gray DR, Huss WJ, Yau JM, et al: Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res 64: 1712-1721, 2004.
30. Sincock PM, Fitter S, Parton RG, Berndt MC, Gamble JR and Ashman LK: PETA-3/CD151, a member of the transmembrane 4 superfamily, is localised to the plasma membrane and endocytic system of endothelial cells, associates with multiple integrins and modulates cell function. J Cell Sci 112: 833-844, 1999.
31. Takeda Y, Kazarov AR, Butterfield CE, et al: Deletion of tetraspanin CD151 results in decreased pathological angiogenesis in vivo and in vitro. Blood 109: 1524-1532, 2007.
32. Wright MD, Geary SM, Fitter S, et al: Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol 24: 5978-5988, 2004.
33. Zuo HJ, Liu ZX, Liu XC, et al: Assessment of myocardial blood perfusion improved by CD151 in a pig myocardial infarction model. Acta Pharmacol Sin 30: 70-77, 2009.
34. Lan RF, Liu ZX, Liu XC, Song YE and Wang DW: CD151 promotes neovascularization and improves blood perfusion in a rat hind-limb ischemia model. J Endovasc Ther 12: 469-478, 2005.
35. Zhang XA, Kazarov AR, Yang X, Bontrager AL, Stipp CS and Hemler ME: Function of the tetraspanin CD151-α6β1 integrin complex during cellular morphogenesis. Mol Biol Cell 13: 1-11, 2002.
36. Yáñez-Mó M, Alfranca A, Cabanas C, et al: Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/ PETA-3 with α3β1 integrin localized at endothelial lateral junctions. J Cell Biol 141: 791-804, 1998.
37. Offersen BV, Borre M and Overgaard J: Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. APMIS 106: 463-469, 1998.
38. Trojan L, Thomas D, Knoll T, Grobholz R, Alken P and Michel MS: Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol Res 32: 97-103, 2004.
39. Zhu W and Dahut WL: Tumor angiogenesis as an early marker of long-term prostate cancer mortality. Future Oncol 6: 341-345, 2010.
40. Sadej R, Romanska H, Baldwin G, et al: CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res 7: 787-798, 2009.
41. Zheng ZZ and Liu ZX: CD151 gene delivery increases eNOS activity and induces ECV304 migration, proliferation and tube formation. Acta Pharmacol Sin 28: 66-72, 2007.
42. Zuo HJ, Lin JY, Liu ZY, et al: Activation of the ERK signaling pathway is involved in CD151-induced angiogenic effects on the formation of CD151-integrin complexes. Acta Pharmacol Sin 31: 805-812, 2010.
43. Mitchell K, Svenson KB, Longmate WM, et al: Suppression of integrin α3β1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and crosstalk to endothelial cells. Cancer Res 70: 6359-6367, 2010.
44. Wang X, Ferreira AM, Shao Q, Laird DW and Sandig M: β3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells. Prostate 63: 65-80, 2005.
45. Mitchell K, Szekeres C, Milano V, et al: α3β1 integrin in epidermis promotes wound angiogenesis and keratinocyte-to-endothelial-cell crosstalk through the induction of MRP3. J Cell Sci 122: 1778-1787, 2009.
46. Dominguez-Jimenez C, Yanez-Mo M, Carreira A, et al: Involvement of α3 integrin/tetraspanins complexes in the angiogenic response induced by angiotensin II. FASEB J 15: 1457-1459, 2001.